Scholarlink

Background <p>Literature on contemporary outcomes of p16-negative OPSCC in India are limited, with existing evidence suggesting poorer prognosis compared to HPV-positive disease.</p> Materials and Methods <p>We conducted a retrospective study of patients with p16-negative oropharyngeal squamous cell carcinoma (OPSCC) who were treated with definitive intensity-modulated radiotherapy (IMRT) to a total dose of 66–70 Gy in 33 fractions over 6.5 weeks. The majority of patients received concurrent chemotherapy while a smaller proportion were treated with radiotherapy alone.</p> Results <p>This retrospective study evaluated treatment outcomes in 181 patients with p16-negative (OPSCC) treated with definitive chemoradiotherapy or Radiation therapy (RT) alone between 2017 and 2024. All patients received intensity-modulated radiotherapy (IMRT) to 66-70 Gy in 33 fractions with 79% receiving concurrent chemotherapy, primarily weekly cisplatin. Median follow-up was 25 months. Locoregional recurrence occurred in 21.5% of patients while distant metastases developed in 26%. The 3 year overall survival and distant metastasis-free survival rates were 65% and 73%, respectively.</p> Conclusion <p>Despite adherence to protocol-based therapy, treatment failures especially distant relapses—remain common, underscoring the aggressive nature of p16-negative disease. Acute toxicities were comparable to available literature but manageable. These findings highlight the need for novel systemic strategies and biomarker-driven treatment intensification in this high-risk subgroup, particularly in resource-limited settings where the burden of p16-negative OPSCC remains high.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Treatment outcomes in p16-negative oropharyngeal squamous cell carcinoma (OPSCC): A real-world retrospective data from a low-middle income countries (LMIC)

  • 期刊论文

  • 发表日期：

    2025年11月23日

查看全文
  • Rohith R. Menon,
  • Trinanjan Basu,
  • Jay Prakash Sahu,
  • Shounak J. Kamat,
  • Ghazala K. Roshan,
  • Ajinkya U. Gadekar,
  • Komal J. Parwani,
  • Parv Modi,
  • Riddhijyoti Talukdar ,
  • Durva Kurkure

摘要

Background

Literature on contemporary outcomes of p16-negative OPSCC in India are limited, with existing evidence suggesting poorer prognosis compared to HPV-positive disease.

Materials and Methods

We conducted a retrospective study of patients with p16-negative oropharyngeal squamous cell carcinoma (OPSCC) who were treated with definitive intensity-modulated radiotherapy (IMRT) to a total dose of 66–70 Gy in 33 fractions over 6.5 weeks. The majority of patients received concurrent chemotherapy while a smaller proportion were treated with radiotherapy alone.

Results

This retrospective study evaluated treatment outcomes in 181 patients with p16-negative (OPSCC) treated with definitive chemoradiotherapy or Radiation therapy (RT) alone between 2017 and 2024. All patients received intensity-modulated radiotherapy (IMRT) to 66-70 Gy in 33 fractions with 79% receiving concurrent chemotherapy, primarily weekly cisplatin. Median follow-up was 25 months. Locoregional recurrence occurred in 21.5% of patients while distant metastases developed in 26%. The 3 year overall survival and distant metastasis-free survival rates were 65% and 73%, respectively.

Conclusion

Despite adherence to protocol-based therapy, treatment failures especially distant relapses—remain common, underscoring the aggressive nature of p16-negative disease. Acute toxicities were comparable to available literature but manageable. These findings highlight the need for novel systemic strategies and biomarker-driven treatment intensification in this high-risk subgroup, particularly in resource-limited settings where the burden of p16-negative OPSCC remains high.